Global Aptamers Market – By Type: DNA Aptamers, RNA Aptamers, XNA Aptamers, Peptide Aptamers, Others; By Application: Therapeutics Development, Diagnostics, Biomarker Discovery, Research, Targeted Drug Delivery; By Technology: SELEX Technology, Custom Aptamer Development, Modified Aptamer Technology, Others; By End User: Biotechnology Companies, Pharmaceutical Companies, Academic and Research Institutions, Diagnostic Centers, CROs; By Mode of Delivery: Intravenous, Intramuscular, Subcutaneous, Oral, Others.
1 | Market Overview
The aptamers market is emerging as a promising frontier in molecular diagnostics, targeted therapeutics, and biosensor development. Aptamers—short, single-stranded DNA or RNA molecules that bind to specific targets—offer advantages over antibodies, including improved thermal stability, easier synthesis, and lower immunogenicity. Their use is expanding in oncology, infectious diseases, drug delivery, and biomarker discovery. Increased academic research, growing biotech interest, and technological advances in SELEX (Systematic Evolution of Ligands by Exponential Enrichment) are driving rapid growth.
2 | Market Size and Forecast
|
Year |
Market Value (USD billion) |
Notes |
|
2019 |
0.83 |
Early commercial adoption and academic research |
|
2024 |
1.52 |
Five-year CAGR: 12.8% |
|
2031 |
4.38 |
Seven-year CAGR: 16.3% |
Growth is led by rising applications in diagnostics and therapeutics, along with ongoing investment in SELEX optimization, AI-guided aptamer design, and nanomaterial-conjugated biosensors.
3 | Primary Market Drivers
4 | Market Challenges
5 | Competitive Landscape
|
Company |
Est. 2024 Share |
Strengths |
Recent Strategic Move |
|
SomaLogic |
18% |
High-throughput proteomics via aptamer arrays |
Expanded diagnostics pipeline with 7,000-target SOMAscan platform |
|
Aptamer Group |
13% |
Custom therapeutic and diagnostic aptamer development |
Partnered with pharma firms for CAR-T targeting ligands |
|
Base Pair Biotechnologies |
11% |
SELEX optimization tools and contract services |
Launched AI-driven aptamer discovery engine |
|
NeoVentures |
9% |
Biosensor integration and nucleic acid modifications |
Deployed aptamer-based toxin detection in food safety systems |
|
Vivonics |
7% |
Point-of-care diagnostic aptamers |
Secured U.S. Department of Defense funding for field diagnostics |
6 | Detailed Market Segmentation
By Type
By Application
By End User
By Region
7 | Technology and Innovation
8 | Regulatory Environment
9 | Strategic Outlook
Copy Content
Need help?
Chat with our team in a minute.